Connor, Clark & Lunn Investment Management Ltd. Arcellx, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Arcellx, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 45,698 shares of ACLX stock, worth $2.52 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
45,698
Previous 36,982
23.57%
Holding current value
$2.52 Million
Previous $2.05 Million
54.87%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ACLX
# of Institutions
186Shares Held
43.4MCall Options Held
73.8KPut Options Held
196K-
Perceptive Advisors LLC New York, NY3.93MShares$217 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$211 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$207 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$169 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$130 Million54.95% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.42B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...